Balanced Outlook on Bristol-Myers Squibb: Strong Earnings Amid Strategic Uncertainties

Analyst Courtney Breen of Bernstein maintained a Hold rating on Bristol-Myers Squibb, with a price target of $58.00.

Courtney Breen’s rating is based on a combination of factors that reflect both positive and cautious elements in Bristol-Myers Squibb’s recent performance. The company reported a significant beat in its second-quarter earnings, with both topline revenue and EPS exceeding expectations. This was driven by contributions from both its Growth and Legacy portfolios, leading to an upward revision in the full-year revenue guidance. However, there are concerns about the quality of these earnings, particularly regarding the reliance on legacy products and other lower-quality items, which has led to a more cautious outlook.
Cobenfy’s slower-than-expected launch and uncertainties surrounding future expansions have also contributed to the Hold rating. While there is potential for positive momentum from upcoming readouts like ADEPT-2 and Iberdomide MRD, the current market conditions and strategic uncertainties have led to a lowered price target of $58. Overall, the Hold rating reflects a balanced view of the company’s strengths and the challenges it faces in sustaining growth and managing its product pipeline effectively.

In another report released on August 1, Citi also maintained a Hold rating on the stock with a $47.00 price target.